Groundbreaking Neuromodulation Therapy Launched for Rheumatoid Arthritis Patients in Southern New Jersey

Revolutionary Neuromodulation Therapy

The Global Neurosciences Institute (GNI) has recently taken a significant step in treating rheumatoid arthritis (RA) with the completion of the first SetPoint System procedures at the AtlantiCare Regional Medical Center in Atlantic City, New Jersey. This innovative technology represents a groundbreaking approach in neuroimmune modulation therapy, aiming to improve the quality of life for those suffering from chronic autoimmune conditions.

The SetPoint System, developed by SetPoint Medical, is the first-ever FDA-approved device for neuroimmune modulation. This therapy caters to adult patients with moderately to severely active RA who have shown an inadequate response or intolerance to other biologic or disease-modifying antirheumatic drugs (DMARDs). The procedure involves a minimally invasive implantation of a small neurostimulator directly on the vagus nerve. This novel approach draws on traditional neurosurgical skills, allowing neurosurgeons like Dr. Rudy Rahme to provide patients with advanced and effective care.

Enhancing Collaborative Care

One of the most remarkable aspects of the SetPoint System lies in the collaborative model of care that underpins its application. Dr. Rahme emphasizes the importance of a team-based approach, working closely with rheumatologists in the region to ensure patients receive streamlined access to this new therapy. With practices across Southern New Jersey, Delaware, and Eastern Pennsylvania, patients can now benefit from this innovative treatment close to home.

Dr. Thomas Kantor, a rheumatologist at Lebanon Internal Medicine Associates, expressed excitement about the new treatment option. Many RA patients struggle with active disease despite trying multiple medications. The SetPoint System offers a fresh alternative that might help restore patients' well-being. This therapy works by utilizing the body’s natural neuroimmune pathways, aiming to reduce inflammation without relying solely on traditional anti-rheumatic drugs.

Understanding Rheumatoid Arthritis

RA is a chronic autoimmune condition that leads to significant joint pain, swelling, and stiffness. The disease affects approximately 1.5 million individuals in the United States, leading to debilitating consequences if not effectively managed. Traditional treatments often involve cumulative immunosuppression, which may increase the risk of infections and various side effects. Consequently, therapies like the SetPoint System, which employ unique mechanisms that do not compromise immune function, are critically needed.

Murthy V. Simhambhatla, president and CEO of SetPoint Medical, underlines the potential impact of this therapy on RA management. By extending the availability of neuroimmune modulation treatment to Southern New Jersey, more individuals can leverage an innovative approach to combat their condition. This development signifies hope for many who have struggled with RA management in the past.

A New Era in RA Treatment

The introduction of the SetPoint System marks an exciting era for rheumatoid arthritis care in Southern New Jersey. With continuous advancements in medical technology, patients can now access state-of-the-art treatments designed to enhance their overall quality of life. For those eager to learn more about this therapy or seek access, rheumatology practices across the region stand ready to assist._g

As the healthcare community embraces these novel therapies, the future looks bright for RA patients, opening doors to possibilities previously thought unattainable. Stay tuned for further innovations in the world of autoimmune disease management.